Neurocrine Biosciences (NBIX) CMO receives stock options and 6,285 RSUs

Rhea-AI Filing Summary

Keswani Sanjay Chandru reported acquisition or exercise transactions in this Form 4 filing.

Neurocrine Biosciences’ Chief Medical Officer receives new equity awards. Sanjay Chandru Keswani was granted a stock option covering 35,827 shares of common stock on February 13, 2026. The option vests monthly, with 1/48 of the shares vesting starting March 13, 2026.

He was also granted 6,285 Restricted Stock Units on the same date. These RSUs vest in four equal annual installments on February 13 of 2027, 2028, 2029, and 2030, with each RSU representing one share of common stock upon settlement.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Keswani Sanjay Chandru

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	35,827	$0.00	--
Grant/Award	Restricted Stock Unit	6,285	$0.00	--

Holdings After Transaction: Stock Option — 35,827 shares (Direct); Restricted Stock Unit — 6,285 shares (Direct)

Footnotes (1)

1. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keswani Sanjay Chandru

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$124.12	02/13/2026		A		35,827		(1)	02/13/2036	Common Stock	35,827	$0	35,827	D
Restricted Stock Unit	(2)	02/13/2026		A		6,285		(3)	(3)	Common Stock	6,285	$0	6,285	D

Explanation of Responses:

1. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

3. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NBIX report for its Chief Medical Officer?

Neurocrine Biosciences reported equity grants to Chief Medical Officer Sanjay Chandru Keswani. He received a stock option for 35,827 shares and 6,285 Restricted Stock Units, both dated February 13, 2026, as part of his compensation package.

How many stock options were granted to the NBIX Chief Medical Officer?

The Chief Medical Officer received a stock option covering 35,827 shares of Neurocrine Biosciences common stock. The award was granted on February 13, 2026 and will vest in 48 equal monthly installments beginning March 13, 2026, subject to continued service.

What is the vesting schedule for the NBIX stock options granted on February 13, 2026?

The stock option vests over four years, with 1/48 of the underlying 35,827 shares becoming vested and exercisable each month. Vesting starts on March 13, 2026, and continues monthly thereafter, aligning the award with long-term service at Neurocrine Biosciences.

How many Restricted Stock Units did the NBIX Chief Medical Officer receive?

He received 6,285 Restricted Stock Units on February 13, 2026. Each RSU represents a contingent right to one share of Neurocrine Biosciences common stock, providing additional equity-based compensation tied to future vesting milestones and continued employment.

What is the vesting schedule for the NBIX Restricted Stock Units granted on February 13, 2026?

The 6,285 Restricted Stock Units vest in four equal annual installments. One quarter of the units will vest on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030, assuming continued service with Neurocrine Biosciences.

Does each NBIX RSU granted to the Chief Medical Officer equal one share?

Yes. Each Restricted Stock Unit granted to the Chief Medical Officer represents a contingent right to receive one share of Neurocrine Biosciences common stock. Delivery of shares occurs as the RSUs vest over the specified annual schedule from 2027 through 2030.